WO2001025397A3 - Compositions and methods for tumor-targeted delivery of effector molecules - Google Patents

Compositions and methods for tumor-targeted delivery of effector molecules Download PDF

Info

Publication number
WO2001025397A3
WO2001025397A3 PCT/US2000/023242 US0023242W WO0125397A3 WO 2001025397 A3 WO2001025397 A3 WO 2001025397A3 US 0023242 W US0023242 W US 0023242W WO 0125397 A3 WO0125397 A3 WO 0125397A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
methods
effector molecule
effector molecules
compositions
Prior art date
Application number
PCT/US2000/023242
Other languages
French (fr)
Other versions
WO2001025397A2 (en
Inventor
David G Bermudes
Ivan C King
Caroline A Clairmont
Stanley L Lin
Michael Belcourt
Original Assignee
Vion Pharmaceuticals Inc
David G Bermudes
Ivan C King
Caroline A Clairmont
Stanley L Lin
Michael Belcourt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc, David G Bermudes, Ivan C King, Caroline A Clairmont, Stanley L Lin, Michael Belcourt filed Critical Vion Pharmaceuticals Inc
Priority to KR1020027004371A priority Critical patent/KR20020059605A/en
Priority to MXPA02003384A priority patent/MXPA02003384A/en
Priority to NZ518354A priority patent/NZ518354A/en
Priority to EP00957764A priority patent/EP1261369A4/en
Priority to AU69334/00A priority patent/AU783714B2/en
Priority to IL14893300A priority patent/IL148933A0/en
Priority to JP2001528552A priority patent/JP2004500042A/en
Priority to CA002386465A priority patent/CA2386465A1/en
Priority to BR0014491-6A priority patent/BR0014491A/en
Publication of WO2001025397A2 publication Critical patent/WO2001025397A2/en
Publication of WO2001025397A3 publication Critical patent/WO2001025397A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
PCT/US2000/023242 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules WO2001025397A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020027004371A KR20020059605A (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
MXPA02003384A MXPA02003384A (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules.
NZ518354A NZ518354A (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
EP00957764A EP1261369A4 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
AU69334/00A AU783714B2 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
IL14893300A IL148933A0 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
JP2001528552A JP2004500042A (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
CA002386465A CA2386465A1 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules
BR0014491-6A BR0014491A (en) 1999-10-04 2000-08-24 Tumor-marked attenuated bacteria, pharmaceutical composition, use of attenuated bacteria, and fusion protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15758199P 1999-10-04 1999-10-04
US15763799P 1999-10-04 1999-10-04
US15750099P 1999-10-04 1999-10-04
US60/157,637 1999-10-04
US60/157,581 1999-10-04
US60/157,500 1999-10-04

Publications (2)

Publication Number Publication Date
WO2001025397A2 WO2001025397A2 (en) 2001-04-12
WO2001025397A3 true WO2001025397A3 (en) 2002-01-24

Family

ID=27388022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023242 WO2001025397A2 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules

Country Status (11)

Country Link
EP (1) EP1261369A4 (en)
JP (1) JP2004500042A (en)
KR (1) KR20020059605A (en)
CN (1) CN1420783A (en)
AU (1) AU783714B2 (en)
BR (1) BR0014491A (en)
CA (1) CA2386465A1 (en)
IL (1) IL148933A0 (en)
MX (1) MXPA02003384A (en)
NZ (1) NZ518354A (en)
WO (1) WO2001025397A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365625B1 (en) 2011-03-31 2016-06-14 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2002500001A (en) 1997-09-10 2002-01-08 ヴァイオン ファーマシューティカルズ、インコーポレーテッド Genetically modified tumor-targeting bacteria with reduced toxicity
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
AU2003219730A1 (en) * 2002-02-07 2003-09-02 Massachusetts Institute Of Technology Anti-pathogen treatements
JP5568208B2 (en) 2003-01-14 2014-08-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Cancer treatment sensitizer
WO2005012363A1 (en) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. Targeting inflammation inducer
CN100435850C (en) * 2004-03-22 2008-11-26 中国医学科学院血液学研究所 Combination of medication produced from attenuated salmonella bacteria possessing effect of radiation protection and anti tumour
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP1781096B1 (en) * 2004-06-29 2016-02-24 AntiCancer, Inc. Prostate cancer selective salmonella typhimurium auxotrophs
ITRM20050422A1 (en) * 2005-08-05 2007-02-06 Consiglio Nazionale Ricerche PROTEIN FACTORS DERMONECROTIZZANTI OF BACTERIAL ORIGIN AND RELATED USES IN MEDICAL FIELD.
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2242516A1 (en) 2008-01-11 2010-10-27 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
FR2960001A1 (en) 2010-05-12 2011-11-18 Univ Rennes RECOMBINANT VECTOR FOR THE PRODUCTION AND SECRETION OF AMINO ACID SEQUENCES OF INTEREST BY PROPIONIC BACTERIA AND ITS APPLICATIONS
CN102604949A (en) * 2011-04-12 2012-07-25 南京大学 Anaerobic tissue selective gene expression method driven by alcohol dehydrogenase promoter and application thereof
WO2013128288A1 (en) * 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
CN102731658B (en) * 2012-05-15 2014-07-30 山东大学 Tat PTD-Endostatin recombination protein, preparation method and application thereof
US9265804B2 (en) * 2013-01-02 2016-02-23 Decoy Biosystems, Inc. Compositions and methods for treatment of cancer using bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2829274A1 (en) 2013-07-25 2015-01-28 Institut National De La Recherche Agronomique Vectors for producing and secreting substance of interest by bacteria and applications thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR101685034B1 (en) * 2015-04-10 2016-12-09 전남대학교 산학협력단 Solid cancer tissue targeting bacterium and use thereof
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN107537027A (en) * 2016-06-23 2018-01-05 南开大学 TNFSF15 albumen is preparing the purposes in treating melanoma medicine
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110913875A (en) * 2017-01-06 2020-03-24 同生运营公司 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN107115533A (en) * 2017-04-01 2017-09-01 广州华津医药科技有限公司 Applications of the genetic engineering bacterium VNP20009 M in treatment malignant sarcomas medicine is prepared
WO2019014391A1 (en) * 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
AU2017430856A1 (en) 2017-09-08 2020-04-02 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
CN108314741B (en) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 Tumor blood vessel targeted anti-cancer peptide NKL-DOTA and preparation method thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN110423772B (en) * 2019-07-17 2023-04-21 上海科技大学 Cytosine base editing plasmid for Acinetobacter baumannii and application of cytosine base editing plasmid
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114438111B (en) * 2020-11-05 2023-08-11 深圳先进技术研究院 Construction of PP2 strict anaerobic salmonella strain and application thereof in tumor treatment
WO2023041809A1 (en) * 2021-09-20 2023-03-23 Pulmobiotics, S.L. Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms
CN116676324B (en) * 2023-07-28 2023-10-27 四川大学华西医院 System and method for constructing and releasing anti-tumor effector protein based on Kil protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040238A1 (en) * 1995-06-07 1996-12-19 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338679A3 (en) * 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
AU731061B2 (en) * 1995-09-06 2001-03-22 Department Of The Army, U.S. Government Bacterial delivery system
JP2002500001A (en) * 1997-09-10 2002-01-08 ヴァイオン ファーマシューティカルズ、インコーポレーテッド Genetically modified tumor-targeting bacteria with reduced toxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040238A1 (en) * 1995-06-07 1996-12-19 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice", CANCER RES., vol. 59, no. 14, July 1999 (1999-07-01), pages 3308 - 3312, XP000857407 *
LOW ET AL.: "Lipid A mutant salmonella with suppressed virulence and TNFa induction retain tumor-targeting in vivo", NATURE BIOTECHNOLOGY, vol. 17, January 1999 (1999-01-01), pages 37 - 41, XP002939412 *
MARR ET AL.: "Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha", GENE THER., vol. 4, no. 11, November 1997 (1997-11-01), pages 1181 - 1188, XP000914782 *
PAWELEK ET AL.: "Tumor targeted salmonella as a novel anticancer vector", CANCER RESEARCH, vol. 57, October 1997 (1997-10-01), pages 4537 - 4544, XP002939411 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy
US9365625B1 (en) 2011-03-31 2016-06-14 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith

Also Published As

Publication number Publication date
WO2001025397A2 (en) 2001-04-12
EP1261369A2 (en) 2002-12-04
AU6933400A (en) 2001-05-10
AU783714B2 (en) 2005-12-01
IL148933A0 (en) 2002-09-12
BR0014491A (en) 2004-03-09
MXPA02003384A (en) 2002-08-20
CA2386465A1 (en) 2001-04-12
NZ518354A (en) 2005-02-25
EP1261369A4 (en) 2006-02-01
KR20020059605A (en) 2002-07-13
CN1420783A (en) 2003-05-28
JP2004500042A (en) 2004-01-08

Similar Documents

Publication Publication Date Title
WO2001025397A3 (en) Compositions and methods for tumor-targeted delivery of effector molecules
AU2002359122A1 (en) Novel compounds
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
CA2292359A1 (en) Novel azalides and methods of making same
AU3057297A (en) Targeted combination immunotherapy of cancer
EP1181013A4 (en) Method and composition for the treatment of cancer
DE60116761D1 (en) Adamantanderivate
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2000066093A3 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
EP1392328A4 (en) Cancer therapy
ZA200500908B (en) Ruthenium anticancer complexes
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
HK1033574A1 (en) Anitumor agents
PL313078A1 (en) Novel bis-naphtalimides for use in treating carcinoma
CA2385996A1 (en) Anticancer agents
AU5705099A (en) Compounds useful as aicarft inhibitors
AUPR118000A0 (en) Therapeutic molecules and methods
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
CA2095352A1 (en) Compositions containing psyllium
AU2001296677A1 (en) Substituted (e)-styryl benzylsulfones for treating proliferative disorders
AU2001267687A1 (en) Ruthenium (ii) compounds for use in the therapy of cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2002249103A1 (en) Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
YU46302A (en) Substituted pyrroles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148933

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2386465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003384

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 528552

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020027004371

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 69334/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 518354

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000957764

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008167141

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027004371

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000957764

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 518354

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518354

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 69334/00

Country of ref document: AU